title: Advances in androgen receptor targeted therapy for prostate cancer.
abstract: Prostate cancer (PCa) is the second leading cause of cancer death in men. Current research findings suggest that the androgen receptor (AR) and its signaling pathway contribute significantly to the progression of metastatic PCa. The AR is a ligand activated transcription factor, where androgens such as testosterone (T) and dihydroxytestosterone (DHT) act as the activating ligands. However in many metastatic PCa, the AR functions promiscuously and is constitutively active through multiple mechanisms. Inhibition of enzymes that take part in androgen synthesis or synthesizing antiandrogens that can inhibit the AR are two popular methods of impeding the androgen receptor signaling axis; however, the inhibition of androgen-independent activated AR function has not yet been fully exploited. This article focuses on the development of emerging novel agents that act at different steps along the androgen-AR signaling pathway to help improve the poor prognosis of PCa patients.
authors.affiliation: Department of Pathology, Karmanos Cancer Institute, Wayne State University School of Medicine, Detroit, Michigan.
authors.forename: Alia
authors.initials: A
authors.lastname: Ahmed
authors.forename: Shadan
authors.initials: S
authors.lastname: Ali
authors.forename: Fazlul H
authors.initials: FH
authors.lastname: Sarkar
mesh_terms: D000726:Androgen Antagonists / Q000737:chemistry / Q000627:therapeutic use*; D000818:Animals; D018931:Antineoplastic Agents, Hormonal / Q000737:chemistry / Q000627:therapeutic use*; D015195:Drug Design; D006801:Humans; D008024:Ligands; D008297:Male; D058990:Molecular Targeted Therapy; D009376:Neoplasms, Hormone-Dependent / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology; D011471:Prostatic Neoplasms / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology; D011944:Receptors, Androgen / Q000187:drug effects* / Q000378:metabolism; D015398:Signal Transduction / Q000187:drug effects; D016896:Treatment Outcome
chemical_list: C410798:AR protein, human; D000726:Androgen Antagonists; D018931:Antineoplastic Agents, Hormonal; D008024:Ligands; D011944:Receptors, Androgen
references.citation: J Steroid Biochem Mol Biol. 2012 Apr;129(3-5):115-28
references.pmid: 22249003
references.citation: Cancer Res. 2012 May 1;72(9):2176-82
references.pmid: 22411952
references.citation: Drug Healthc Patient Saf. 2011;3:107-19
references.pmid: 22279415
references.citation: Lancet Oncol. 2013 Feb;14(2):e48
references.pmid: 23487849
references.citation: J Steroid Biochem Mol Biol. 2013 Nov;138:248-56
references.pmid: 23792785
references.citation: Clin Cancer Res. 2011 Jun 15;17(12):3876-83
references.pmid: 21680543
references.citation: J Clin Oncol. 2013 May 20;31(15):1866-73
references.pmid: 23589550
references.citation: Bioorg Med Chem Lett. 2012 Mar 1;22(5):2105-9
references.pmid: 22310230
references.citation: Curr Treat Options Oncol. 2012 Jun;13(2):189-200
references.pmid: 22539224
references.citation: J Urol. 2013 May;189(5):1715
references.pmid: 23594628
references.citation: Clin Cancer Res. 2009 Jan 1;15(1):39-47
references.pmid: 19118031
references.citation: Cancer Prev Res (Phila). 2011 Sep;4(9):1495-506
references.pmid: 21680704
references.citation: Ther Adv Urol. 2012 Aug;4(4):167-78
references.pmid: 22852027
references.citation: Mol Endocrinol. 2012 Dec;26(12):1967-79
references.pmid: 23023561
references.citation: Pharm Res. 2009 Aug;26(8):1874-80
references.pmid: 19421843
references.citation: PLoS One. 2011 Mar 09;6(3):e17850
references.pmid: 21408027
references.citation: Lancet. 2010 Apr 24;375(9724):1437-46
references.pmid: 20398925
references.citation: Curr Oncol. 2012 Dec;19(Suppl 3):S22-31
references.pmid: 23355790
references.citation: Cancer Res. 2012 Mar 15;72(6):1494-503
references.pmid: 22266222
references.citation: Core Evid. 2013;8:27-35
references.pmid: 23589709
references.citation: BJU Int. 2012 Feb;109 Suppl 1:22-9
references.pmid: 22239226
references.citation: Prostate. 2007 Apr 1;67(5):509-20
references.pmid: 17221841
references.citation: Int J Oncol. 2013 Jan;42(1):35-43
references.pmid: 23152004
references.citation: Int J Cancer. 2012 Aug 1;131(3):662-72
references.pmid: 22275114
references.citation: Cancer Res. 2008 Jun 1;68(11):4447-54
references.pmid: 18519708
references.citation: Endocr Relat Cancer. 2010 Aug 16;17(3):R195-212
references.pmid: 20576802
references.citation: EMBO J. 2011 Sep 13;30(19):3962-76
references.pmid: 21915096
references.citation: Clin Cancer Res. 2012 Apr 1;18(7):1848-54
references.pmid: 22451619
references.citation: Int J Cancer. 2010 Feb 1;126(3):775-89
references.pmid: 19653278
references.citation: Curr Oncol Rep. 2013 Apr;15(2):69-75
references.pmid: 23341368
references.citation: Oncologist. 2011;16(11):1487-97
references.pmid: 22048000
references.citation: Differentiation. 2008 Jul;76(6):641-59
references.pmid: 18462433
references.citation: Biochemistry. 2011 May 17;50(19):4105-13
references.pmid: 21466228
references.citation: J Cell Biochem. 2009 Jun 1;107(3):516-27
references.pmid: 19330806
references.citation: Urol Oncol. 2009 May-Jun;27(3):251-7
references.pmid: 19414113
references.citation: J Int Med Res. 2012;40(4):1217-26
references.pmid: 22971474
references.citation: Nat Med. 2004 Jan;10(1):33-9
references.pmid: 14702632
references.citation: Biochim Biophys Acta. 2012 Jan;1825(1):11-7
references.pmid: 21963805
references.citation: Annu Rev Med. 2013;64:1-13
references.pmid: 23020876
references.citation: Br J Cancer. 2003 Aug 4;89(3):552-6
references.pmid: 12888829
references.citation: Curr Oncol Rep. 2013 Apr;15(2):105-12
references.pmid: 23371447
references.citation: J Clin Oncol. 2003 Jul 15;21(14):2673-8
references.pmid: 12860943
references.citation: Cancer. 1997 Nov 1;80(9):1755-9
references.pmid: 9351544
references.citation: PLoS One. 2012;7(3):e32514
references.pmid: 22403669
references.citation: Proc Natl Acad Sci U S A. 2011 Jul 19;108(29):11878-83
references.pmid: 21730179
references.citation: J Natl Cancer Inst. 2011 Nov 16;103(22):1665-75
references.pmid: 21917607
references.citation: Lancet Oncol. 2009 Oct;10(10):981-91
references.pmid: 19796750
references.citation: Cancer Res. 2006 Oct 15;66(20):10064-72
references.pmid: 17047070
references.citation: Cancer Res. 2012 Jul 15;72(14):3457-62
references.pmid: 22710436
references.citation: Cancer Res. 2008 Jul 1;68(13):5469-77
references.pmid: 18593950
references.citation: Endocr Relat Cancer. 2013 Mar 26;20(2):R49-64
references.pmid: 23447570
references.citation: Clin Cancer Res. 2011 Apr 1;17(7):1649-57
references.pmid: 21372223
references.citation: N Engl J Med. 2012 Sep 27;367(13):1187-97
references.pmid: 22894553
references.citation: Proc Natl Acad Sci U S A. 2010 Sep 28;107(39):16759-65
references.pmid: 20823238
references.citation: Cancer Res. 2013 Jan 15;73(2):483-9
references.pmid: 23117885
references.citation: Prostate. 2013 Sep;73(12):1291-305
references.pmid: 23765603
references.citation: BMC Cancer. 2012 Feb 02;12:54
references.pmid: 22299707
references.citation: PLoS One. 2012;7(3):e33011
references.pmid: 22412975
references.citation: Expert Rev Anticancer Ther. 2012 Feb;12(2):131-3
references.pmid: 22316360
references.citation: CA Cancer J Clin. 2013 Jan;63(1):11-30
references.pmid: 23335087
references.citation: Cancer Cell. 2013 Jan 14;23(1):35-47
references.pmid: 23260764
references.citation: J Steroid Biochem Mol Biol. 2013 Mar;134:80-91
references.pmid: 23146910
references.citation: Science. 2009 May 8;324(5928):787-90
references.pmid: 19359544
references.citation: Steroids. 2013 Jun;78(6):548-54
references.pmid: 23380368
references.citation: Recenti Prog Med. 2012 Feb;103(2):74-8
references.pmid: 22430753